ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases. The Company´s lead product candidate has the potential to treat multiple types of solid tumors and hematologic malignancies by targeting multiple components of the immune system to activate profound anti-tumor responses. ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.
Location: United States, Indiana, York
Total raised: $100.27M
Investors 6
| Date | Name | Website |
| 07.06.2022 | Lightspeed... | lsvp.com |
| - | Mission Bi... | missionbio... |
| 21.04.2021 | MK Venture... | mk-vc.com |
| 08.06.2022 | VentureLab | venturelab... |
| 07.06.2022 | GIMV | gimv.com |
| - | BackBone V... | backbone.v... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 18.09.2024 | Series C | $11M | - |
| 07.06.2022 | Series B | $74M | GIMV |
| 11.12.2019 | Series A | $15.27M | - |
Mentions in press and media 20
| Date | Title | Description |
| 22.10.2025 | Promising results in oncology research | iOnctura, a clinical-stage precision oncology company focused on neglected and hard-to-treat cancers, conducted a Phase Ib study, AION-02 (NCT05586516), on its investigating oral autotaxin (ATX) inhibitor, cambritaxestat (IOA-289), in pati... |
| 18.09.2024 | ImmunOs Therapeutics Secures $11 Million to Propel Cancer Immunotherapy Forward | ImmunOs Therapeutics AG, a biopharmaceutical company based in Schlieren, Switzerland, has successfully raised $11 million in a Series C funding round. This financial boost comes from a mix of existing investors and a new player, Double Poin... |
| 18.09.2024 | Immunos Therapeutics raises USD11 million | ImmunOs’ lead program IOS-1002 is currently tested in a Phase Ia dose escalation clinical trial as a monotherapy and in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). IOS-1002 is a novel, multifunctional immunotherapy a... |
| 17.09.2024 | ImmunOs Therapeutics Raises $11M in Series C Funding | ImmunOs Therapeutics, a Schlieren, Switzerland-based biopharmaceutical company developing HLA-based technology platform, raised $11M in Series C funding. The round wad led by Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and su... |
| 17.09.2024 | ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base | Existing investors and new investor Double Point Ventures join forces to support ImmunOs Therapeutics Investment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers September 17, 2024 – ImmunOs Therapeutics AG, ... |
| 15.08.2024 | Clinical advancements at ImmunOs Therapeutics and Noema Pharma | ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, has expanded its ongoing Phase I clinic... |
| 20.10.2023 | Early-stage pharmaceutical companies make strides in cancer- and immunotherapy | |
| 18.01.2023 | Green light for ImmunOs Therapeutics first clinical trial | |
| 08.06.2022 | Walmart convenes startups and corporates to work on a dirty problem: decarbonizing its truck and home delivery fleets | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Two years ago Walmart said it was aiming to reduce its carbon emissions to zero by 2040—and, as t... |
| 07.06.2022 | ImmunOs Therapeutics Raises $74M in Series B Financing | ImmunOs Therapeutics AG, a Schlieren (Zurich Area), Switzerland-based biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, raised ... |
Show more